{"id":"https://openalex.org/W7223973767","doi":"https://doi.org/10.22034/jpcm.2026.590054.1384","title":"Listeriolysin O, alone and in combination with Cisplatin and Carfilzomib, modulates MDR1, MRP1, and BCRP expression in Cisplatin-sensitive and -resistant ovarian cancer cells","display_name":"Listeriolysin O, alone and in combination with Cisplatin and Carfilzomib, modulates MDR1, MRP1, and BCRP expression in Cisplatin-sensitive and -resistant ovarian cancer cells","publication_year":2026,"publication_date":"2026-10-01","ids":{"openalex":"https://openalex.org/W7223973767","doi":"https://doi.org/10.22034/jpcm.2026.590054.1384"},"language":"en","primary_location":{"id":"pmh:oai:doaj.org/article:1579562312ec4388aaaf11764a914ade","doi":"https://doi.org/10.22034/jpcm.2026.590054.1384","is_oa":false,"landing_page_url":"https://doaj.org/article/1579562312ec4388aaaf11764a914ade","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Preventive and Complementary Medicine, Vol 5, Iss 3, Pp 168-177 (2026)","raw_type":"article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["doaj"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063233504","display_name":"Navid Ghasemzadeh","orcid":"https://orcid.org/0000-0002-0359-3572","observed_orcids":["https://orcid.org/0000-0002-0359-3572"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Navid Ghasemzadeh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060406367","display_name":"Javad Zavar Reza","orcid":"https://orcid.org/0000-0003-4065-0772","observed_orcids":["https://orcid.org/0000-0003-4065-0772"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Javad Zavar Reza","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5118825648","display_name":"Amir Hossein Fatehi Marj","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amir Hossein Fatehi Marj","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001879908","display_name":"Moein Moradi","orcid":"https://orcid.org/0000-0003-1045-8691","observed_orcids":["https://orcid.org/0000-0003-1045-8691","https://orcid.org/0000-0002-9166-654X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Moein Moradi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159975954","display_name":"Hooriya Takhtechian","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hooriya Takhtechian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5101464591","display_name":"Sadegh Zarei","orcid":"https://orcid.org/0000-0003-0177-2865","observed_orcids":["https://orcid.org/0000-0003-0177-2865"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sadegh Zarei","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.80473298,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/listeriolysin-o","display_name":"listeriolysin O","score":0.925000011920929},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.828000009059906},{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":1.0},{"id":"https://openalex.org/keywords/multidrug-resistance","display_name":"multidrug resistance","score":0.843999981880188},{"id":"https://openalex.org/keywords/abc-efflux-transporters","display_name":"ABC efflux transporters","score":0.8840000033378601},{"id":"https://openalex.org/keywords/mdr1","display_name":"MDR1","score":0.9760000109672546},{"id":"https://openalex.org/keywords/mrp1","display_name":"MRP1","score":0.9990000128746033},{"id":"https://openalex.org/keywords/abcg2","display_name":"ABCG2","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.9449999928474426},{"id":"https://openalex.org/keywords/chemosensitization","display_name":"chemosensitization","score":0.8579999804496765},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6029999852180481},{"id":"https://openalex.org/keywords/pore-forming-toxins","display_name":"pore-forming toxins","score":0.8009999990463257},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.902999997138977},{"id":"https://openalex.org/keywords/a2780-cells","display_name":"A2780 cells","score":0.7429999709129333},{"id":"https://openalex.org/keywords/chemoresistance-reversal","display_name":"chemoresistance reversal","score":0.7260000109672546},{"id":"https://openalex.org/keywords/gene-downregulation","display_name":"gene downregulation","score":0.6909999847412109}],"concepts":[{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.7143999934196472},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.6676999926567078},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.5485000014305115},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.536899983882904},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5306000113487244},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5069000124931335},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.43140000104904175},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42179998755455017},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.41999998688697815},{"id":"https://openalex.org/C200082930","wikidata":"https://www.wikidata.org/wiki/Q22327148","display_name":"Efflux","level":2,"score":0.4198000133037567},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.3955000042915344},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37880000472068787},{"id":"https://openalex.org/C44312359","wikidata":"https://www.wikidata.org/wiki/Q286958","display_name":"ATP-binding cassette transporter","level":4,"score":0.3644999861717224},{"id":"https://openalex.org/C512196","wikidata":"https://www.wikidata.org/wiki/Q4650095","display_name":"Abcg2","level":5,"score":0.358599990606308},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.32109999656677246},{"id":"https://openalex.org/C133936738","wikidata":"https://www.wikidata.org/wiki/Q643839","display_name":"Multiple drug resistance","level":3,"score":0.3089999854564667},{"id":"https://openalex.org/C105580179","wikidata":"https://www.wikidata.org/wiki/Q188928","display_name":"Messenger RNA","level":3,"score":0.3052000105381012},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.3050999939441681},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.30160000920295715},{"id":"https://openalex.org/C48023723","wikidata":"https://www.wikidata.org/wiki/Q856198","display_name":"Real-time polymerase chain reaction","level":3,"score":0.2921999990940094},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.28999999165534973},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.2833000123500824},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2822999954223633},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.2816999852657318},{"id":"https://openalex.org/C175656101","wikidata":"https://www.wikidata.org/wiki/Q56646","display_name":"Chinese hamster ovary cell","level":3,"score":0.2761000096797943},{"id":"https://openalex.org/C2778707650","wikidata":"https://www.wikidata.org/wiki/Q412902","display_name":"P-glycoprotein","level":4,"score":0.26589998602867126},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2583000063896179}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:doaj.org/article:1579562312ec4388aaaf11764a914ade","doi":"https://doi.org/10.22034/jpcm.2026.590054.1384","is_oa":false,"landing_page_url":"https://doaj.org/article/1579562312ec4388aaaf11764a914ade","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Preventive and Complementary Medicine, Vol 5, Iss 3, Pp 168-177 (2026)","raw_type":"article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2952353820","https://openalex.org/W2370029590","https://openalex.org/W1967055836","https://openalex.org/W2533526916","https://openalex.org/W4362592779","https://openalex.org/W1973688267","https://openalex.org/W3172749791","https://openalex.org/W2358594570","https://openalex.org/W3203926487","https://openalex.org/W1511099714"],"abstract_inverted_index":{"Background:":[0],"Overexpression":[1],"of":[2,39,55,99,152,184,234,257],"ABC":[3,236],"efflux":[4,237],"transporters":[5],"(MDR1,":[6],"MRP1,":[7,57,101,154],"BCRP)":[8],"drives":[9],"chemoresistance":[10,258],"in":[11,44,60,158,197,213,224,259],"ovarian":[12,67,260],"cancer.":[13],"We":[14],"test":[15],"a":[16,133,146,219,255,265],"novel":[17],"strategy":[18],"combining":[19],"the":[20,37,51,114,174,178,204,232],"pore-forming":[21],"toxin":[22],"LLO":[23,130,216],"with":[24,46,84,111,226],"cisplatin":[25,227],"and":[26,43,48,58,63,76,88,102,148,155,200,228,249,263],"carfilzomib":[27],"to":[28,35,113],"overcome":[29],"multidrug":[30],"resistance.Objectives:":[31],"This":[32,239],"study":[33],"aimed":[34],"evaluate":[36],"effects":[38],"LLO,":[40,85],"both":[41,159,198],"alone":[42],"combination":[45,143,183,206,225],"Cis":[47],"CFZ,":[49,87],"on":[50,136],"mRNA":[52,96,157],"expression":[53,97,233],"levels":[54,98],"MDR1,":[56,100,153],"BCRP":[59,103,156],"cisplatin-sensitive":[61],"(A2780S)":[62],"cisplatin-resistant":[64,271],"(A2780CisR)":[65],"human":[66],"carcinoma":[68],"cell":[69,160],"lines.Methods:":[70],"In":[71,139],"this":[72],"experimental":[73],"study,":[74],"A2780S":[75],"A2780CisR":[77,214],"cells":[78,262],"were":[79,104,194],"treated":[80],"for":[81,165,270],"72":[82],"hours":[83],"Cis,":[86],"their":[89],"combinations":[90,191],"(Cis/LLO,":[91],"CFZ/LLO,":[92],"Cis/CFZ/LLO).":[93],"The":[94,169,181],"relative":[95],"quantified":[105],"using":[106,122],"quantitative":[107],"real-time":[108],"PCR":[109],"(qRT-PCR),":[110],"normalization":[112],"GAPDH":[115],"housekeeping":[116],"gene.":[117],"Statistical":[118],"analysis":[119],"was":[120,173,186],"performed":[121],"one-way":[123],"ANOVA":[124],"followed":[125],"by":[126],"Tukey's":[127],"post-hoc":[128],"test.Results:":[129],"monotherapy":[131],"had":[132],"minimal":[134],"impact":[135],"transporter":[137],"expression.":[138],"stark":[140],"contrast,":[141],"all":[142],"regimens":[144],"induced":[145],"profound":[147],"statistically":[149],"significant":[150],"downregulation":[151],"lines":[161],"(p":[162],"<":[163],"0.05":[164],"overall":[166],"treatment":[167],"effect).":[168],"triple-combination":[170],"therapy":[171],"(Cis/CFZ/LLO)":[172],"most":[175],"potent,":[176],"demonstrating":[177],"strongest":[179],"suppression.":[180],"dual":[182],"CFZ/LLO":[185],"also":[187],"highly":[188,266],"effective.":[189],"Notably,":[190],"involving":[192],"CFZ":[193],"consistently":[195],"potent":[196],"sensitive":[199],"resistant":[201],"cells,":[202],"while":[203],"Cis/LLO":[205],"showed":[207],"differential":[208],"efficacy,":[209],"being":[210],"less":[211],"effective":[212],"cells.Conclusion:":[215],"acts":[217],"as":[218],"powerful":[220],"chemosensitizing":[221],"agent":[222],"that,":[223],"carfilzomib,":[229],"drastically":[230],"downregulate":[231],"critical":[235],"transporters.":[238],"multi-mechanistic":[240],"strategy,":[241],"which":[242],"concurrently":[243],"targets":[244],"DNA":[245],"integrity,":[246],"proteasome":[247],"function,":[248],"plasma":[250],"membrane":[251],"stability,":[252],"effectively":[253],"overcomes":[254],"cornerstone":[256],"cancer":[261],"represents":[264],"promising":[267],"therapeutic":[268],"approach":[269],"disease.":[272]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2026-10-28T00:00:00"}